Veru prices $25.2M public offering of common stock and warrants; net proceeds ~$23.4M for enobosarm study

VERU INC.

Offering includes 1.4M common shares + 7M pre-funded warrants and 8.4M Series A and 8.4M Series B warrants at $3.00/unit.
Gross proceeds expected ~$25.2M; net proceeds ~$23.4M after underwriting discounts and expenses.
Closing expected on or about October 31, 2025, subject to customary conditions.
Proceeds primarily to fund Phase 2b PLATEAU clinical study of enobosarm; also for working capital and general corporate purposes.
Series A warrants expire 5 years from issuance; Series B warrants expire 3 years or upon meeting specific clinical milestones and stock price triggers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.